1. Home
  2. TCPC vs REPL Comparison

TCPC vs REPL Comparison

Compare TCPC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock TCP Capital Corp.

TCPC

BlackRock TCP Capital Corp.

HOLD

Current Price

$3.87

Market Cap

354.1M

Sector

Finance

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$8.60

Market Cap

407.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCPC
REPL
Founded
2006
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
354.1M
407.1M
IPO Year
2006
2018

Fundamental Metrics

Financial Performance
Metric
TCPC
REPL
Price
$3.87
$8.60
Analyst Decision
Sell
Hold
Analyst Count
2
9
Target Price
$3.50
$5.67
AVG Volume (30 Days)
667.2K
6.0M
Earning Date
05-07-2026
05-21-2026
Dividend Yield
18.23%
N/A
EPS Growth
N/A
5.25
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.43
$1.50
52 Week High
$8.05
$13.24

Technical Indicators

Market Signals
Indicator
TCPC
REPL
Relative Strength Index (RSI) 42.70 76.20
Support Level $3.43 $8.24
Resistance Level $4.46 $9.01
Average True Range (ATR) 0.13 0.65
MACD -0.04 0.34
Stochastic Oscillator 28.89 95.38

Price Performance

Historical Comparison
TCPC
REPL

About TCPC BlackRock TCP Capital Corp.

BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: